Program
brelovitug
Also written as “Brelovitug 300 mg”, “Brelovitug 900 mg” and “Brelovitug (BJT-778)”.
Its studies are mostly in Hepatitis D · Hepatitis D, Chronic, led by Mirum Pharmaceuticals.
Furthest: phase 3, since Mar 26, 20254 company-led studies, 4 open or runningNext primary completion: Jun 30, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mirum Pharmaceuticals | 44 open or running | phase 3since Mar 26, 2025 | Mar 26, 2025 | Jun 30, 2027phase 3 · NCT07200908 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 26, 2025First study: phase 3 study in Hepatitis DFirst studyNCT06907290 · 150 enrolled · United States, Australia, Bulgaria and more
- Sep 16, 2025Phase 3 study in Hepatitis DNCT07200908 · 172 planned · Austria, Czechia, France and more
- Dec 19, 2025Phase 3 study in Hepatitis DNCT07298330 · 80 enrolled · United States, Belgium, Bulgaria and more
- Mar 2, 2026Phase 3 study in Hepatitis D, ChronicNCT07454837 · 120 planned · Austria, Czechia, France and more
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Hepatitis DNCT07200908
- Aug 31, 2027Primary completion: phase 3 study in Hepatitis D, ChronicNCT07454837
- May 2029Primary completion: phase 3 study in Hepatitis DNCT06907290
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07454837Hepatitis D, Chronic · Austria, Czechia, France and more | 3 | Recruiting | Aug 31, 2027 | 120 |
| NCT07298330Hepatitis D · United States, Belgium, Bulgaria and more | 3 | Active, not recruiting | Aug 2026 | 80 |
| NCT07200908Hepatitis D · Austria, Czechia, France and more | 3 | Recruiting | Jun 30, 2027 | 172 |
| NCT06907290Hepatitis D · United States, Australia, Bulgaria and more | 3 | Active, not recruiting | May 2029 | 150 |
How it is read
Names in the registry
- “Brelovitug 300 mg”, 3 entries
- “Brelovitug 900 mg”, 2 entries
- “Brelovitug (BJT-778)”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis D, 3 studies
- Hepatitis D, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.